- Home
- POAI vs CHRO Comparison
POAI vs CHRO Comparison
Compare POAI & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- CHRO
- Stock Information
- Founded
- POAI 2002
- CHRO 2002
- Country
- POAI United States
- CHRO United States
- Employees
- POAI N/A
- CHRO N/A
- Industry
- POAI Industrial Specialties
- CHRO
- Sector
- POAI Health Care
- CHRO
- Exchange
- POAI Nasdaq
- CHRO Nasdaq
- Market Cap
- POAI 9.7M
- CHRO 11.3M
- IPO Year
- POAI N/A
- CHRO 2024
- Fundamental
- Price
- POAI $1.45
- CHRO $1.68
- Analyst Decision
- POAI Hold
- CHRO Strong Buy
- Analyst Count
- POAI 1
- CHRO 1
- Target Price
- POAI N/A
- CHRO N/A
- AVG Volume (30 Days)
- POAI 483.7K
- CHRO 104.9K
- Earning Date
- POAI 03-27-2025
- CHRO 03-04-2025
- Dividend Yield
- POAI N/A
- CHRO N/A
- EPS Growth
- POAI N/A
- CHRO N/A
- EPS
- POAI N/A
- CHRO N/A
- Revenue
- POAI $1,484,223.00
- CHRO N/A
- Revenue This Year
- POAI N/A
- CHRO N/A
- Revenue Next Year
- POAI $569.48
- CHRO N/A
- P/E Ratio
- POAI N/A
- CHRO N/A
- Revenue Growth
- POAI N/A
- CHRO N/A
- 52 Week Low
- POAI $0.55
- CHRO $0.45
- 52 Week High
- POAI $3.67
- CHRO $4.84
- Technical
- Relative Strength Index (RSI)
- POAI 50.83
- CHRO 50.49
- Support Level
- POAI $1.39
- CHRO $1.59
- Resistance Level
- POAI $1.97
- CHRO $1.99
- Average True Range (ATR)
- POAI 0.14
- CHRO 0.29
- MACD
- POAI -0.02
- CHRO -0.06
- Stochastic Oscillator
- POAI 14.88
- CHRO 41.44
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.